167 related articles for article (PubMed ID: 38658931)
1. CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling.
Wang X; Shi A; Liu J; Kong W; Huang Y; Xue W; Yang F; Huang J
Cancer Cell Int; 2024 Apr; 24(1):147. PubMed ID: 38658931
[TBL] [Abstract][Full Text] [Related]
2. Loss of cell division cycle‑associated 5 promotes cell apoptosis by activating DNA damage response in clear cell renal cell carcinoma.
Huang X; Huang Y; Lv Z; Wang T; Feng H; Wang H; Du S; Wu S; Shen D; Wang C; Li H; Wang B; Ma X; Zhang X
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642672
[TBL] [Abstract][Full Text] [Related]
3. CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation.
Fu G; Xu Z; Chen X; Pan H; Wang Y; Jin B
J Cancer; 2020; 11(9):2408-2420. PubMed ID: 32201512
[TBL] [Abstract][Full Text] [Related]
4. KLF5-mediated CDCA5 expression promotes tumor development and progression of epithelial ovarian carcinoma.
Chen X; Zhou M; Ma S; Wu H; Cai H
Exp Cell Res; 2023 Aug; 429(1):113645. PubMed ID: 37247719
[TBL] [Abstract][Full Text] [Related]
5. TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.
Jin X; Wang D; Lei M; Guo Y; Cui Y; Chen F; Sun W; Chen X
J Transl Med; 2022 May; 20(1):191. PubMed ID: 35509067
[TBL] [Abstract][Full Text] [Related]
6. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma.
Xu J; Zhu C; Yu Y; Wu W; Cao J; Li Z; Dai J; Wang C; Tang Y; Zhu Q; Wang J; Wen W; Xue L; Zhen F; Liu J; Huang C; Zhao F; Zhou Y; He Z; Pan X; Wei H; Zhu Y; He Y; Que J; Luo J; Chen L; Wang W
EBioMedicine; 2019 Aug; 46():54-65. PubMed ID: 31324603
[TBL] [Abstract][Full Text] [Related]
7. CDCA5, Transcribed by E2F1, Promotes Oncogenesis by Enhancing Cell Proliferation and Inhibiting Apoptosis via the AKT Pathway in Hepatocellular Carcinoma.
Chen H; Chen J; Zhao L; Song W; Xuan Z; Chen J; Li Z; Song G; Hong L; Song P; Zheng S
J Cancer; 2019; 10(8):1846-1854. PubMed ID: 31205541
[TBL] [Abstract][Full Text] [Related]
8. CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathway.
Ji J; Shen T; Li Y; Liu Y; Shang Z; Niu Y
Oncol Rep; 2021 Mar; 45(3):921-932. PubMed ID: 33650660
[TBL] [Abstract][Full Text] [Related]
9. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
10. Cell division cycle associated 5 promotes colorectal cancer progression by activating the ERK signaling pathway.
Shen A; Liu L; Chen H; Qi F; Huang Y; Lin J; Sferra TJ; Sankararaman S; Wei L; Chu J; Chen Y; Peng J
Oncogenesis; 2019 Feb; 8(3):19. PubMed ID: 30808873
[TBL] [Abstract][Full Text] [Related]
11. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
[TBL] [Abstract][Full Text] [Related]
12. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
13. LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway.
Zhang X; Wu H; Yan X; Ma J; Chen Z
Cells; 2022 Nov; 11(22):. PubMed ID: 36429034
[TBL] [Abstract][Full Text] [Related]
14. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
[TBL] [Abstract][Full Text] [Related]
15. METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression.
Liu Z; Sun T; Piao C; Zhang Z; Kong C
J Transl Med; 2021 May; 19(1):209. PubMed ID: 33985542
[TBL] [Abstract][Full Text] [Related]
16. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
17. ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR/ERK signaling pathway.
Xu J; Wang Y; Jiang J; Yin C; Shi B
J Transl Med; 2023 Jan; 21(1):56. PubMed ID: 36717944
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
[TBL] [Abstract][Full Text] [Related]
19. TRAF2 promotes M2-polarized tumor-associated macrophage infiltration, angiogenesis and cancer progression by inhibiting autophagy in clear cell renal cell carcinoma.
Xu Y; Li L; Yang W; Zhang K; Zhang Z; Yu C; Qiu J; Cai L; Gong Y; Zhang Z; Zhou J; Gong K
J Exp Clin Cancer Res; 2023 Jul; 42(1):159. PubMed ID: 37415241
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling.
Li JK; Chen C; Liu JY; Shi JZ; Liu SP; Liu B; Wu DS; Fang ZY; Bao Y; Jiang MM; Yuan JH; Qu L; Wang LH
Mol Cancer; 2017 Jun; 16(1):111. PubMed ID: 28659173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
